NO178109B - N-alkyl-3-fenyl-3-(2-alkylthiofenoksy)propylaminer og en farmasöytisk formulering - Google Patents
N-alkyl-3-fenyl-3-(2-alkylthiofenoksy)propylaminer og en farmasöytisk formulering Download PDFInfo
- Publication number
- NO178109B NO178109B NO923710A NO923710A NO178109B NO 178109 B NO178109 B NO 178109B NO 923710 A NO923710 A NO 923710A NO 923710 A NO923710 A NO 923710A NO 178109 B NO178109 B NO 178109B
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- compounds
- norepinephrine
- pharmaceutically acceptable
- compound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 125000006308 propyl amino group Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 abstract description 17
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 16
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 16
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- -1 pyrosulfate Chemical compound 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000012154 norepinephrine uptake Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- JZFUHAGLMZWKTF-UHFFFAOYSA-N 3-chloro-1-phenylpropan-1-ol Chemical compound ClCCC(O)C1=CC=CC=C1 JZFUHAGLMZWKTF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DYKZDPNOXOTEHQ-UHFFFAOYSA-N 1-(3-chloro-1-phenylpropoxy)-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1OC(CCCl)C1=CC=CC=C1 DYKZDPNOXOTEHQ-UHFFFAOYSA-N 0.000 description 1
- PQWGFUFROKIJBO-UHFFFAOYSA-N 1-(3-chlorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC(Cl)=C1 PQWGFUFROKIJBO-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical class NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- DGAPFMMBOPPHLE-UHFFFAOYSA-N C(CCC(=O)O)(=O)O.CNCCC(SC1=C(C=CC=C1)CC)C1=CC=CC=C1 Chemical compound C(CCC(=O)O)(=O)O.CNCCC(SC1=C(C=CC=C1)CC)C1=CC=CC=C1 DGAPFMMBOPPHLE-UHFFFAOYSA-N 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BWKLGNFNVWRDIA-UHFFFAOYSA-N Cl.CNCCC(SC1=C(C=CC=C1)C(C)(C)C)C1=CC=CC=C1 Chemical compound Cl.CNCCC(SC1=C(C=CC=C1)C(C)(C)C)C1=CC=CC=C1 BWKLGNFNVWRDIA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- TWXQUDJNKSGXNE-UHFFFAOYSA-N N-ethyl-3-phenyl-3-(2-propylphenyl)sulfanylpropan-1-amine formic acid Chemical compound C(=O)O.C(C)NCCC(SC1=C(C=CC=C1)CCC)C1=CC=CC=C1 TWXQUDJNKSGXNE-UHFFFAOYSA-N 0.000 description 1
- VZIYNJNIJMZLNZ-UHFFFAOYSA-N N-methyl-3-(2-methylphenyl)sulfanyl-3-phenylpropan-1-amine hydrochloride Chemical compound Cl.CNCCC(SC1=C(C=CC=C1)C)C1=CC=CC=C1 VZIYNJNIJMZLNZ-UHFFFAOYSA-N 0.000 description 1
- BJNFEFRMOLGLCS-UHFFFAOYSA-N P(=O)(O)(O)O.C(C)NCCC(SC1=C(C=CC=C1)C)C1=CC=CC=C1 Chemical compound P(=O)(O)(O)O.C(C)NCCC(SC1=C(C=CC=C1)C)C1=CC=CC=C1 BJNFEFRMOLGLCS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000005080 cortical synaptosome Anatomy 0.000 description 1
- 238000003350 crude synaptosomal preparation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- IUTPYKBKYDVRDB-UHFFFAOYSA-N n-methyl-3-(2-methylphenyl)sulfanyl-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)SC1=CC=CC=C1C IUTPYKBKYDVRDB-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- PYNUOAIJIQGACY-UHFFFAOYSA-N propylazanium;chloride Chemical compound Cl.CCCN PYNUOAIJIQGACY-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Foreliggende oppfinnelse vedrører nye N-alkyl-3-fenyl-3-(2-substituerte fenoksy)propylaminer som er selektive og potente inhibitorer av norefinifrin opptaket og en farmasøytisk formulering.
I det siste tiår har forståelsen for den biologiske rollen til nerveceller (neuroner) blitt øket. Spesielle neuroner har vært implisert i bestemte sykdommer. Foreliggende oppfinnelse tilveiebringer forbindelser som inhiberer presynaptisk biogenisk aminopptak i minst en type neuro, norefinefrin-neuron.
Norefinefrinneuroner finnes hvor som helst i hjernen og er også kjent for å eksistere i andre organer i kroppen, så som blæren. Forbindelsene ifølge foreliggende oppfinnelse stimulerer neuronene indirkete ved å inhibere norefinefrinopptaket. Binyrekjertlene er kjent for å utskille norefinefrin med respons overfor stress. Norefinefrin blir dermed også kalt noradrenalin.
Pasienter med Alzheimers og Korsakoffs syndrom og depresjon kan mangle norefinefrin. Den farmasøytiske formuleringen ifølge foreliggende oppfinnelse er nyttig for behandling av forstyrrelser assosiert med ubalanse av norefinefrin. Schildkraut, Neuropharmacology of Affective Disorders, 427
(1973) er en meget god kilde for bakgrunnsinformasjon.
U.S-patent nr. 4.018.895 beskriver en klasse N-alkyl-3-fenyl-3-fenoksypropylaminer som er lik de som blir krevet i foreliggende oppfinnelse. Eksempel 2 beskriver spesielt N-metyl-3-feiryl-3-(2-metoksyfenoksy)propylamin.
Ifølge foreliggende oppfinnelse er det tilveiebragt en forbindelse med formel (I) hvor X er C-L-C^alkyl thio, og Y er C-^-Cg-alkyl eller et farmasøytisk akseptabelt syreaddisjonssalt derav.
Forbindelsen, N-metyl-3-fenyl-3-(2-metylrhiofenoksy)-propylamin, eller et farmasøytisk akseptabelt syreaddisjonssalt derav er også beskrevet.
Oppfinnelsen vedrører også en farmasøytisk formulering kjennetegnet ved at den omfatter forbindelsene ifølge krav 1 eller 2 eller et farmasøytisk akseptabelt syreaddisjonssalt derav assosiert med en eller flere farmasøytisk akseptable bærere, fortynningsmidler eller excipienter for denne.
En fordel med disse forbindelsene er at de er mere potente norefinefrinopptak inhibitorer enn metoksy-substituerte forbindelser.
Den farmasøytiske formuleringen kan anvendes for behandling av forskjellige forstyrrelser som er blitt knyttet til redusert neurotransmisjon av norefinefrin i pattedyr inkludert medikamentmisbruk, depressjon, narkolepsi, paniske forstyrrelser, bulimi og beslektede psykiatriske forstyrrelser. Forbindelsene kan også anvendes for behandling av urininkontinens på grunn av den kjente intraksjonen av norefinefrin med urinsystemet.
Foretrukkene forbindelser er de hvor Y er metyl. Den mest foretrukne forbindelsen i denne serien er N-metyl-3-fenyl-3-(2-metylthiofenoksy)propylamin.
Forbindelsene ifølge denne oppfinnelsen kan eksistere som individuelle stereoisomerer samt som racemisk blanding. Forbindelsene ifølge foreliggende oppfinnelse vil derfor innbefatte ikke bare d,1-racemater, men også deres respektive optiske aktive d- og 1-isomerer.
Som angitt ovenfor innbefatter oppfinnelsen farmasøytisk akseptable syreaddisjonssalter av forbindelser definert med overnevnte formel. På grunn av at forbindelsen ifølge denne oppfinnelsen er aminer er de basiske av natur og reagerer derfor med et hvilket som helst antall uorganiske og organiske syrer for å danne farmasøytisk akseptable syreaddisjonssalter. På grunn av at de frie aminene ifølge oppfinnelsen er vanligvis oljer ved romtemperatur er det foretrukket for å lette håndteringen å omdanne de frie aminene til deres tilsvarende farmasøytisk akseptable syreaddisjonssalter, som er rutinemessige faste stoffer ved romtemperatur. Syrer som vanligvis blir anvendt for å danne slike salter omfatter uorganiske syrer så som saltsyre, hydrobromsyre, hydrojodsyre, svovelsyre og fosforsyre, samt organiske syrer så som paratoluensulfonsyre, metansulfonsyre og saltsyre, parabromfenylsulfonsyre, karbonsyre, ravsyre, sitronsyre, benzosyre og eddiksyre, og beslektede uorganiske og organiske syrer.
Slike farmasøytisk akseptable salter innbefatter derfor sulfat, pyrosulfat, bisulfat, sulfit, blisulfit, fosfat, monohydrogenfosfat, dihydrogenfosfat, metafosfat, pyrofosfat, klorid, bromid, iodid, acetat, propionat, decanoat, caprylat, akrylat, format, isobutyrat, caprat, heptanoat, propiolat, oksalat, malonat, succinat, suberat, sebacat, fumarat, maleat, butyn-1,4-dioat, heksyn-1,6-dioat, benzoat, klor-benzoat, metylbenzoat, dinitrobenzoat, hydroksybenzoat, metoksybenzoat, ftalat, tereftalat, sulfonat, xylensulfonat, fenylacetat, fenylpropionat, fenylbutyrat, citrat, lactat, p-hydroksybutyrat, glycollat, maleat, tartrat, metansulfonat, propansulfonat, naftalen-l-sulfonat, naftalen-2-sulfonat, mandelat og lignende salter. Foretrukkne farmasøytisk akseptable syreaddisjonssalter omfatter de som blir dannet med mineralsyrer så som saltsyre og hydrobromsyre, og spesielt de som blir dannet med organiske syrer så som oksalsyre og maleinsyre.
Følgende forbindelser illustrerer ytterligere forbindelsene betraktet innenfor rammen av foreliggende oppfinnelse: N-etyl-3-fenyl-3-(2-metylthiofenoksy)propylaminfosfat, N-metyl-3-fenyl-3-(2-t-butylthiofenoksy)-propylaminhydroklorid, N-etyl-3-fenyl-3-(2-n-propylthiofenoksy)propylaminformat, N-metyl-3-fenyl-3-(2-etylthiofenoksy)propylaminsuccinat, N-mety1-3-f enyl-3-(2-i sopropylthiofenoksy)propylaminhydro-klorid.
Forbindelsene ifølge denne oppfinnelsen i form av deres frie baser er oljer med høyt kokepunkt, men hvite krystallinske faste stoffer i form av deres syreaddisjonssalter. Forbindelsene kan bli fremstilt på flere måter. En nyttig fremgangsmåte for fremstilling av forbindelsene representert ved overnevnte former blir fortrinnsvis utført som beskrevet i US-patent nr. 4.018.895.
Ifølge en ytterligere utførelsesform av foreliggende oppfinnelse er det tilveiebragt en fremgangsmåte for fremstilling av en forbindelse med formel (I) som omfatter omsetning av et 3-fenylpropylaminderivat med formel: med en forbindelse med formel:
hvor Q og J er hydroksy eller halo; og P er hydrogen eller en beskyttende gruppe; etterfulgt i tilfeller når P er en beskyttende gruppe av avspaltning, og i det tilfellet hvor P er halogen ved amidering med et amin med formel YNHg, og eventuelt, hvor det er ønskelig å danne et farmasøytisk akseptabelt syreaddisjonssalt, ved saltdannelse av eventuelt tilstedeværende fri base.
Eksempel 1
Fremstilling av N- metyl- 3- fenyl- 3-( 2- metylthiofenoksy)-propylaminhydroklorid
En 10,80 g porsjon klorpropiofenon ble løst opp i 100 ml metanol i en 500 ml, 3-halset, rundbundet flaske. Flasken ble utstyrt med et nitrogeninnløp og et termometer. Reaksjonsblandingen ble omrørt ved hjelp av en magnetisk rørestav og ble holdt under en nitrogenatmosfære. Mens blandingen ble avkjølt i et isbad ble 2,03 g natriumborhydrid sakte tilsatt. BLandingen ble fjernet fra isbadet og deretter omrørt i omtrent 2 timer ved romtemperatur.
Blandingen ble deretter avdampet til en gul olje og fortynnet med omtrent 100 ml vann. Blandingen ble ekstrahert fra vannet ved vasking 3 ganger med eter. Eterblandingen ble deretter vasket to ganger med vann og en gang med mettet natrium-kloridoppløsning. Den resulterende blandingen ble tørket over natriumsulfat og avdampet til 11,2 g gult mellomprodukt omfattende 3-klor-l-fenyl-l-propanol.
En 4,99 g porsjon av mellomproduktet 3-klor-l-fenyl-l-propanol som fremstilt ovenfor ble plassert i en 3-halset, 250 ml rund-bunnet flaske som var blitt skylt, med nitrogen. Flasken ble utstyrt med et termometer, et nitrogeninnløp og en ytterligere trakt. Forbindelsen, 3,52 g 2-metylthiofenol og 7,69 g trifenylfosfin ble magnetisk omrørt i 40 ml tetrahydrofuran. En 4,61 ml del dietylazodikarboksylat ble dråpevis tilsatt til denne blandingen. Temperaturen til reaksjonsblandingen blir holdt rundt 25°C ved anvendelse av et isbad. Tilsetningstrakten ble skylt med tetrahydrofuran og reaksjonsblandingen ble omrørt over natt ved omtrent romtemperatur. I løpet av tilsetning av dietylazodikarboksylat ble blandingen tykk, opak og gul i farve. Etter omtrent 1 time ble blandingen klargjort til en gul opp-løsning. Reaksjonsblandingen ble avdampet for å tilveiebringe et gult faststoff. Heksan ble tilsatt til det faste stoffet og blandingen ble grundig ristet.
Uoppløselig trifenylfosfinoksyd ble deretter sug-filtrert og heksan ble på nytt tilsatt til det faste stoffet, og blandingen ble ristet og filtrert på ny. Filtratene ble avdampet til 6,63 g klar olje. Den klare oljen ble deretter løst opp i eter. En 2 N natriumhydroksydoppløsning ble deretter tilsatt. Natriumhydroksydlaget ble fjernet og det organiske laget ble vasket en gang med vann og en gang med mettet natriumkloridoppløsning. Oppløsningen ble deretter tørket over natriumsulfat. Den resulterende forbindelsen 1-(3-klor-l-fenyl-propoksy)-2-metylthiobenzen ble deretter amidert ved omsetning med metylamin (40$ i vann) i etanol ved 130°C i 3 timer. Etter avdampning av etanol ble vann tilsatt til den resulterende gule oljen. Blandingen ble ekstrahert to ganger med eter, og vasket to ganger med vann og en gang med en oppløsning av saltvann. Produktet ble tørket over natriumsulfat.
Produktet ble renset via flammekromatografi ved våt appli-sering ved anvendelse av et metylenklorid, metanol og ammoniumhydroksyd system i det forholdet er 100:5:1. En 870 mg del av produktet ble isolert.
Aminet ble løst opp i metanol og 1,05 ekvivalenter 12 N HC1 ble tilsatt. Ved rekrystallisering ble en 850 mg del off-white krystaller oppnådd.
Smeltepunktet til dette faste stoffet var 143° til 144,5°C.
Analyse:
Teori: C, 63,04; E, 6,85; N, 4,32;
Funnet: C, 63,08; H, 6,94; N, 4,23.
Som angitt ovenfor er forbindelsene ifølge denne oppfinnelsen nyttige for inhibering av opptaket av norefinefrin og norefinefrinopptaket kan følgelig inhiberes ved å admini-strere forbindelsene til pattedyret en farmasøytisk effektiv mengde.
Betegnelsen "farmasøytisk effektiv mengde" som anvendt heri, representerer en mengde av en forbindelse ifølge oppfinnelsen som kan inhibere opptaket av norefinefrin. Den bestemt dosen av forbindelsen som blir administrert vil selvfølgelig bli bestemt av de bestemte omstendighetene som omgir tilfeller, inkludert forbindelsen som blir administrert, admini-strer ingsveien , den bestemte tilstanden som blir behandlet og lignende hensyn. Forbindelsene kan bli administrert ved forskjellige veier, inkludert oralt, rekatalt, transdermalt, subkutant, intravenøst, intramuskulaert eller intranasalt. Den orale administrasjonsveien er foretrukket.
Forbindelsene ifølge oppfinnelsen inhiberer opptaket av norefinefrin i pattedyr på en uventet selektiv og potent måte. En typisk daglig dose vil inneholde fra omtrent 0,01 mg/kg til omtrent 20 mg/kg av den aktive forbindelsen ifølge denne oppfinnelsen. Foretrukne daglige doser vil være fra omtrent 0,05 mg/kg til 10 mg/kg, fortrinnsvis fra omtrent 0,1 mg/kg til 5 mg/kg.
Forskjellige fysiologiske funksjoner har vist seg å være influert av norefinefrinnivående i kroppen. Forbindelsene ifølge foreliggende oppfinnelse antas derfor å ha evnen til å behandle forskjellige forstyrrelser i pattedyr som er assosiert med unormale norefinefrinnivåer i kroppen.
Det følgende eksperimentet ble utført for å demonstrere evnen som forbindelsene ifølge foreliggende oppfinnelse har for å inhibere opptaket av norefinefrin. Denne generelle prosedyren er angitt av Wong et al., 6 Drug Development research 397
(1985).
Hann Sprague-Dawley rotter med vekt på 150-250 g ble avlivet og hjernene ble øyeblikkelig fjernet. Cerebral cortices ble homogenisert i 9 volum av et medium inneholdende 0,32 M sucrose og 10 mM glucose. Rå synaptosomale preparater ble isolert etter differensial sentrifugering ved 1000 x g i 10 minutter og 17.000 x g i 28 minutter. Sluttpelletene ble suspendert i det samme mediet og oppbevart på is frem til bruk i løpet av samme dag.
Synaptosomalt opptak av<3>H-norefinefrin (<3>E-NE) ble bestemt som følger. Corticale synaptosomer (ekvivalent til 1 mg protein) ble inkubert ved 37"C i 5 minutter i en 5 ml Krebs-bikarbonatmedium også inneholdende 10 mM glucose, 0,1 mM iproniazid, 1 mM askorbinsyre, 0,17 mM EDTA og 50 nM<3>H-NE. Reaksjonsblandingen ble øyeblikkelig fortynnet med 2 ml isavkjølt Krebs-bikarbonatbuffer og filtrert under vakuum med en cellehøster (Brandel, Gaithersburg, MD). Filtrene ble skylt to ganger med omtrent 5 ml is-avkjølt 0,9$ saltvann og opptaket av radiomerket NE ble vurdert ved Væskescintilla-sjonstelling. Akkumulering av<3>H-NR ved 4°C ble betraktet å være bakgrunn og ble subtrahert fra alle målingene. Konsentrasjonen av testforbindelsen som var nødvendig for å inhibere 50$ av 3H -NE akkumuleringen (IC50verdien) ble bestemt ved lineær regressjonsanalyse.
Resultatene av vurderingen er angitt nedenfor i tabell I. Som vist i tabellen ble forbindelsen vurdert for å bestemme konsentrasjonen av testforbindelsen som var nødvendig for å inhibere 50% norefinifrin som indikert ved IC5Ø.
Disse data viser klart at metylthioderivatene ifølge oppfinnelsen er betraktelig mere aktive enn metoksyderivatet ifølge teknikkens stand.
Forbindelsene ifølge foreliggende oppfinnelse blir fortrinnsvis formulert før administreringen. En annen utførelsesform ifølge foreliggende oppfinnelse er derfor en farmasøytisk formulering omfattende en forbindelse ifølge oppfinnelsen og en farmasøytisk akseptabel bærer, fortynningsmiddel eller excipient derav.
Foreliggende farmasøytiske formuleringer blir fremstilt ved kjente fremgangsmåter ved anvendelse av velkjente og lett tilgjengelige ingredienser. Ved fremstilling av sammensetningene ifølge foreliggende oppfinnelse vil det aktive ingredienset vanligvis bli blandet med en bærer som kan være i form av en kapsel, pute, papir eller annen beholder. Når bæreren virker som et fortynningsmiddel kan den være et fast, halvfast eller flytende materiale som virker som en bærer, excipient eller medium for det aktive ingredienset. Sammensetningene kan derfor være i form av tabletter, piller, pulvere, tabletter, puter, elixirer, suspensjoner, emul-sjoner, oppløsninger, siruper, salver inneholdende for eksempel opp til 10 vekt-# av den aktive forbindelsen, bløte og harde gelatinkapsler, stikkpiller, sterile injiserbare oppløsninger og sterilt pakkede pulvere.
Noen eksempler på egnede bærere, excipienter og fortynningsmidler innbefatter lactose, dekstrose, sucrose, sorbitol, mannitol, stivelse, gummiacacia, kalsiumfosfat, alginater, tragakanth, gelatin, kalsiumsilikat, mikrokrystallinsk cellulose, poyvinylpyrrolidon, cellulose, vann, sirup, metylcellulose, metyl- og propylhydroksybenzoater, talk, magnesiumstearat og mineralolje. Formuleringene kan i tillegg innbefatte smøremidler, fuktemidler, emulgeringsmidler og suspenderingsmidler, konserveringsmidler, søtningsmidler eller smaksmidler. Sammensetningene ifølge oppfinnelsen kan bli formulert for å tilveiebringe hurtig, vedvarende eller forsinket frigjøring av det aktive ingredienset etter administrering til pasienten ved anvendelse av fremgangsmåter som er velkjente innenfor fagområdet.
Sammensetningene blir fortrinnsvis formulert i en enhets-doseform, i det hver dosering inneholder fra omtrent 5 til omtrent 500 mg, mere vanlig er fra omtrent 25 til omtrent 300 mg av det aktive ingredienset. Betegnelsen "enhetsdoserings-form" refererer til fysisk diskree enheter egnet som enhetsdoseringer for mennesker og andre pattedyr i det hver enhet inneholder en forutbestemt mengde av det aktive materialet beregnet å produsere den ønskede terapeutiske effekten ved assosiasjon med en egnet farmasøytisk bærer.
Følgende formuleringseksempler skal illustrere oppfinnelsen.
Formulering 1
Harde gelatinkapsler blir fremstilt ved anvendelse av følgende ingredienser:
Overnevnte ingredienser blir blandet og fylt inn i harde gelatinkapsler i mengder på 460 mg.
Formulering 2
Tabletter som hver inneholder 60 mg aktivt ingrediens blir fremstilt som følger:
Det aktive ingredienset, stivelse og cellulose blir sendt gjennom en nr. 45 mesh US-sikt og grundig blandet. Opp-løsningen av polyvinylpyrrolidon blir blandet med de resulterende pulverene som deretter blir sendt gjennom en nr. 14 mesh US-sikt. Granulene som blir dannet på denne måten blir tørket ved 50° C og sendt gjennom om en nr. 18 mesh US-sikt. Natriumkarboksymetylstivelse, magnesiumstearat og talk, på forhånd sendt gjennom en nr. 60 mesh US-sikt, blir deretter tilsatt til granulene som etter blanding blir komprimert på en tablettmaskin for å tilveiebringe tabletter som hver veier 150 mg.
Claims (3)
1.
Forbindelse,karakterisert vedat den har formel (I)
hvori X er C1-C4-alkylthio og Y er C^-Cg-alkyl eller et farmasøytisk akseptabelt syreaddisjonssalt derav.
2.
Forbindelse,karakterisert vedat den er N-metyl-3-fenyl-3-(2-metylrhiofenoksy)propylamin, eller et farmasøytisk akseptabelt syreaddisjonssalt derav.
3.
En farmasøytisk formulering,karakterisertved at den omfatter en forbindelse ifølge krav 1 eller 2 eller et farmasøytisk akseptabelt syreaddisjonssalt derav assosiert med en eller flere farmasøytisk akseptable bærere, fortynningsmidler eller excipienter for denne.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/766,993 US5281624A (en) | 1991-09-27 | 1991-09-27 | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
Publications (4)
Publication Number | Publication Date |
---|---|
NO923710D0 NO923710D0 (no) | 1992-09-24 |
NO923710L NO923710L (no) | 1993-03-29 |
NO178109B true NO178109B (no) | 1995-10-16 |
NO178109C NO178109C (no) | 1996-01-24 |
Family
ID=25078150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO923710A NO178109C (no) | 1991-09-27 | 1992-09-24 | N-alkyl-3-fenyl-3-(2-alkylthiofenoksy)propylaminer og en farmasöytisk formulering |
Country Status (23)
Country | Link |
---|---|
US (1) | US5281624A (no) |
EP (1) | EP0534756A3 (no) |
JP (2) | JP3256291B2 (no) |
KR (1) | KR100221180B1 (no) |
CN (1) | CN1033580C (no) |
AT (1) | ATE124934T1 (no) |
AU (1) | AU655075B2 (no) |
BR (2) | BR9203743A (no) |
CA (2) | CA2079162A1 (no) |
CZ (1) | CZ281817B6 (no) |
DE (1) | DE69203424T2 (no) |
FI (1) | FI111250B (no) |
HU (1) | HU215519B (no) |
IL (1) | IL103277A (no) |
MX (1) | MX9205433A (no) |
MY (1) | MY108304A (no) |
NO (1) | NO178109C (no) |
NZ (1) | NZ244460A (no) |
RU (1) | RU2057120C1 (no) |
SK (1) | SK280480B6 (no) |
TW (1) | TW249225B (no) |
YU (1) | YU87192A (no) |
ZA (1) | ZA927240B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087765B2 (en) * | 1995-06-07 | 2006-08-08 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6017965A (en) * | 1993-02-08 | 2000-01-25 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
CA2227410A1 (en) * | 1995-07-24 | 1997-02-06 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
JP2001502302A (ja) * | 1996-09-19 | 2001-02-20 | アメリカン・ホーム・プロダクツ・コーポレイション | 尿失禁を治療する方法 |
US6586427B2 (en) | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
CZ297346B6 (cs) * | 1998-04-09 | 2006-11-15 | Pharmacia & Upjohn Company | Pouzití reboxetinu pro výrobu léku k lécbe nervových poruch |
US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
EP1905757A1 (en) * | 1999-04-06 | 2008-04-02 | Sepracor Inc. | Derivatives of Venlafaxine and methods of preparing and using the same |
CA2716369C (en) | 1999-05-24 | 2013-05-14 | Mitsubishi Tanabe Pharma Corporation | Phenoxypropylamine compounds |
ES2246485T3 (es) * | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
PT1455770E (pt) * | 2001-11-30 | 2007-09-06 | Lilly Co Eli | Uso de inibidores de reabsorção da norepinefrina para o tratamento dos transtornos de tiques. |
HUP0402619A3 (en) * | 2001-12-11 | 2008-04-28 | Lilly Co Eli | Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure |
AU2004227945B2 (en) * | 2003-04-04 | 2006-10-26 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
EP1660065A2 (en) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
ITMI20061987A1 (it) | 2006-10-16 | 2008-04-17 | Archimica Srl | Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine. |
EP3697754A1 (en) * | 2017-10-16 | 2020-08-26 | Esteve Pharmaceuticals, S.A. | Propanamine derivatives for treating pain and pain related conditions |
CN113121394B (zh) * | 2019-12-30 | 2022-11-08 | 中国药科大学 | 一种苯氧乙酸类衍生物的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4194009A (en) * | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
US4018895A (en) * | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
US4313896A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Aryloxyphenylpropylamines |
US4584404A (en) * | 1974-01-10 | 1986-04-22 | Eli Lilly And Company | Substituted phenoxyphenylproply dimethylamines |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
IL89854A (en) * | 1988-04-08 | 1994-02-27 | Lilly Co Eli | Phenoxypropanamines, the process for their preparation and medicinal preparations containing them |
-
1991
- 1991-09-27 US US07/766,993 patent/US5281624A/en not_active Expired - Lifetime
-
1992
- 1992-09-22 ZA ZA927240A patent/ZA927240B/xx unknown
- 1992-09-22 SK SK2908-92A patent/SK280480B6/sk unknown
- 1992-09-22 CZ CS922908A patent/CZ281817B6/cs not_active IP Right Cessation
- 1992-09-23 NZ NZ244460A patent/NZ244460A/en unknown
- 1992-09-23 MY MYPI92001704A patent/MY108304A/en unknown
- 1992-09-24 MX MX9205433A patent/MX9205433A/es not_active IP Right Cessation
- 1992-09-24 AT AT92308709T patent/ATE124934T1/de not_active IP Right Cessation
- 1992-09-24 IL IL103277A patent/IL103277A/xx not_active IP Right Cessation
- 1992-09-24 NO NO923710A patent/NO178109C/no unknown
- 1992-09-24 HU HU9203051A patent/HU215519B/hu not_active IP Right Cessation
- 1992-09-24 DE DE69203424T patent/DE69203424T2/de not_active Expired - Fee Related
- 1992-09-24 EP EP19920308708 patent/EP0534756A3/en not_active Withdrawn
- 1992-09-25 JP JP25632792A patent/JP3256291B2/ja not_active Expired - Fee Related
- 1992-09-25 JP JP4256333A patent/JPH05238996A/ja not_active Withdrawn
- 1992-09-25 CA CA002079162A patent/CA2079162A1/en not_active Abandoned
- 1992-09-25 FI FI924305A patent/FI111250B/fi active
- 1992-09-25 KR KR1019920017511A patent/KR100221180B1/ko not_active IP Right Cessation
- 1992-09-25 CA CA002079161A patent/CA2079161C/en not_active Expired - Fee Related
- 1992-09-25 BR BR929203743A patent/BR9203743A/pt not_active Application Discontinuation
- 1992-09-25 AU AU25370/92A patent/AU655075B2/en not_active Ceased
- 1992-09-25 YU YU87192A patent/YU87192A/sh unknown
- 1992-09-25 RU SU5052706/04A patent/RU2057120C1/ru not_active IP Right Cessation
- 1992-09-26 CN CN92111081A patent/CN1033580C/zh not_active Expired - Fee Related
- 1992-11-10 TW TW081108988A patent/TW249225B/zh active
-
1997
- 1997-04-30 BR BR1100384-7A patent/BR1100384A/pt active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO178109B (no) | N-alkyl-3-fenyl-3-(2-alkylthiofenoksy)propylaminer og en farmasöytisk formulering | |
KR960003808B1 (ko) | 3-아릴옥시-3-치환된 프로판아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
IE52170B1 (en) | (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,antidepressant | |
AU622942B2 (en) | Fluoxetine analog | |
JPH07149644A (ja) | 血管形成および血管形成性疾患を抑制する方法 | |
US5238959A (en) | 3-phenyloxy-3-phenyl propanamines | |
NO172043B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater | |
JPH0217179A (ja) | 環置換2―アミノ―1,2,3,4―テトラヒドロナフタレン類 | |
JPH07223948A (ja) | ターナー症候群を抑制するための医薬組成物 | |
AU611794B2 (en) | Improvements in or relating to propanamine derivatives | |
DK151805B (da) | Analogifremgangsmaade til fremstilling af 20,21-di-nor-eburnameninderivater eller farmaceutisk acceptable additionssalte deraf | |
EP0537915B1 (en) | N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors | |
US7361655B2 (en) | Pharmaceutically effective compounds | |
DE69828522T2 (de) | Antithrombotische mittel | |
JPH02235868A (ja) | グアニジン誘導体 | |
WO2001007434A2 (de) | Indolderivate und deren verwendung als 5ht2a liganden | |
EP0591581B1 (en) | N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines | |
DE69724548T2 (de) | Substituierte 2,3-Aryl-Benzothiophene und ihre östrogene Aktivität | |
EP0318234A2 (en) | Improvements in or relating to selective serotonin uptake inhibitors | |
DE60125416T2 (de) | Stabilisierte formulierungen von 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophen und deren salze | |
JPH08269045A (ja) | 3−ベンジル−ベンゾチオフェン類 | |
CA2257535A1 (en) | A method for minimizing the uterotrophic effect of droloxifene |